Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ).
Fusen Pharmaceutical said its wholly owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology has received Chinese regulatory approval to market Compound Potassium Hydrogen Phosphate Injection, a Class B reimbursable drug used as a parenteral phosphate supplement and for treating hypophosphatemia in adult and pediatric patients when oral or enteral therapy is unsuitable. The new-generation phosphorus–potassium formulation, designed to rapidly correct phosphorus deficiency while stabilizing membrane potential and reducing risks such as rhabdomyolysis and arrhythmia, targets a domestic market that generated RMB343 million in 2023 and RMB413 million in 2024, and its launch broadens Fusen’s nutritional supplement portfolio and strengthens its positioning in hospital nutrition and electrolyte management, potentially enhancing its presence in China’s parenteral nutrition segment.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited is a Cayman Islands–incorporated drugmaker listed in Hong Kong that develops and markets prescription pharmaceutical products in China, with a growing focus on hospital-use therapies and nutritional and clinical support drugs, including parenteral nutrition supplements.
Average Trading Volume: 960,906
Technical Sentiment Signal: Buy
Current Market Cap: HK$588.2M
See more insights into 1652 stock on TipRanks’ Stock Analysis page.